How much is Rapport Therapeutics worth in 2026?

Rapport Therapeutics has a current valuation of N/A based on their PIPE round and secondary market data.

How much funding has Rapport Therapeutics raised?

Rapport Therapeutics has raised N/A in total funding across 2 funding rounds.

Rapport Therapeutics

Drug Discovery

Rapport Therapeutics valuation and funding history | Last updated: September 30, 2024 | 2 funding rounds

Current Valuation

N/A

As of September 30, 2024

Total Funding Raised

N/A

Across 2 rounds

Last Round

PIPE

$112.4M

Last Funding

Sep 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
September 30, 2024	PIPE	$112.4M	N/A	-
August 7, 2023	Early Stage VC (Series B)	$150.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Rapport Therapeutics is currently valued at N/A as of September 30, 2024.

Track Rapport Therapeutics Valuation Updates

Get notified when Rapport Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Rapport Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Rapport Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Rapport Therapeutics Worth in 2026?

Rapport Therapeutics is a leading private company in the Drug Discovery sector. Track Rapport Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Rapport Therapeutics Valuation is Determined

Private company valuations like Rapport Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.